Adverse Events Could Halt Neuralink

The core risk is not a slower launch, it is a forced reset of the whole program. Brain implants sit in the FDA's highest scrutiny bucket, where one death, stroke, infection, device migration, or removal problem can trigger trial pauses, protocol changes, added monitoring, or years of extra evidence work. That matters more for Neuralink because its product requires a skull opening and implanted threads inside brain tissue, so safety is the gate before scale, revenue, or broader indications.

• Neuralink already entered human trials with a history of regulator concern. Reporting on the 2022 rejection said the FDA focused on battery safety, thread migration, and whether the implant could be removed without damaging brain tissue. Those are not paperwork issues, they are the exact kinds of failures that can stop an implant program cold.
  2 fda 3 cnbc
• The first human implant showed why the bar is so high. After surgery in early 2024, some threads retracted from the brain, cutting the number of working electrodes. Neuralink said performance later stabilized, but the episode showed that even a non catastrophic failure can force design and surgical changes before a trial can expand.
  1 sacra 4 cnbc 5 theguardian
• Competitors make a different trade off. Synchron places its device through a blood vessel rather than open brain surgery, which lowers procedural complexity but captures fewer signals. In practice, lower invasiveness can mean a friendlier safety profile with regulators and hospitals, even if performance is weaker than Neuralink's higher bandwidth approach.
  1 sacra 6 sacra

The field is heading toward a split where the winners are not just the systems with the best cursor control, but the ones that can build a clean safety record across many implants. If Neuralink keeps improving surgery and device stability, its higher bandwidth approach can justify the added risk. If safety events accumulate, less invasive rivals gain time, trust, and trial access.